大阪市立総合医療センターは、大阪市都島区にある病院。 同地に、運営主体である地方独立行政法人大阪市民病院機構の理事局も所在する。

During the past decade, Osaka City General Hospital conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 16 clinical trials were completed, i.e. on average, 32.7% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 11 clinical trials were completed. i.e. 47.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Osaka City General Hospital" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Pfizer" with 4 trials sponsored, "Takeda" with 4 trials sponsored and "Daiichi Sankyo, Inc." with 4 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Osaka City General Hospital" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Kurashiki Central Hospital" with 2 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator. Other collaborators include 44 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "Osaka City General Hospital" are "Carcinoma, Non-Small-Cell Lung" (5 trials), "Non-small Cell Lung Cancer" (4 trials), "Non-Small Cell Lung Cancer" (3 trials), "Adenocarcinoma" (2 trials) and "Axial Spondyloarthritis" (2 trials). Many other conditions were trialed in "Osaka City General Hospital" in a lesser frequency.

Most popular intervention types in "Osaka City General Hospital" are "Drug" (52 trials), "Other" (7 trials), "Biological" (3 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Cisplatin" (5 trials), "Pemetrexed" (5 trials), "Carboplatin" (4 trials) and "Docetaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "Osaka City General Hospital" are 59 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Osaka City General Hospital". undefined are not yet recruiting, 18 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Osaka City General Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Osaka City General Hospital, 8 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".